<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>stocks on FinanClub</title>
    <link>https://finan.club/tags/stocks/</link>
    <description>Recent content in stocks on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 30 Dec 2023 09:04:52 +0000</lastBuildDate><atom:link href="https://finan.club/tags/stocks/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CSCO</title>
      <link>https://finan.club/us/csco/</link>
      <pubDate>Sat, 30 Dec 2023 09:04:52 +0000</pubDate>
      
      <guid>https://finan.club/us/csco/</guid>
      <description>score:-196
Chances: Cisco Systems (CSCO) concluded the recent trading session at $50.52, signifying a +0.08% move from its prior day&amp;rsquo;s close. The outlook for CSCO stock depends on trends for cloud computing, plus corporate and telecom networks amid the shift to remote work.</description>
    </item>
    
    <item>
      <title>PATH</title>
      <link>https://finan.club/us/path/</link>
      <pubDate>Sat, 30 Dec 2023 09:02:55 +0000</pubDate>
      
      <guid>https://finan.club/us/path/</guid>
      <description>score:713
Chances: UiPath is well positioned to have a phenomenal decade. UiPath and CrowdStrike will continue their 2023 success into the new year. UiPath did an excellent job in 2023, accelerating revenue and controlling costs. Both of these stocks are massive holdings for Ark Invest, but Wood likes one better at current prices.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
